-
Rheumatology: Comparison of the efficacy of baricitinib, tofacitinib and bDMARDS in the treatment of rheumatoid arthritis
Time of Update: 2022-04-17
In addition, we compared drug retention and changes in DAS28, HAQ-DI, and CDAI from baseline to 3 months after treatment initiation .
Compared with baricitinib, the adjusted 1-year response rate was consistently lower in the TNFi group, with a difference of 4.
-
Cyclosporine: Showdown, it turns out that I have so many misunderstandings!
Time of Update: 2022-04-17
Judging from the listed adverse reactions, my "temper" seems to be quite big, but in fact, most patients usually experience vomiting, drowsiness, headache, rapid heartbeat and other symptoms after oral administration of cyclosporine, and only a few patients will Moderate and severe liver and kidney damage, but this damage is reversible [1], don't be too afraid of me~
-
ARD: a large-scale analysis of longitudinal skin gene expression in systemic sclerosis
Time of Update: 2022-04-17
In early diffuse cutaneous SSc , immune cell and fibroblast characteristics declined over time, and overall skin gene expression normalized .
In early diffuse cutaneous SSc , immune cell and fibroblast characteristics declined over time, and overall skin gene expression normalized .
-
Br J Dermatol: A new model of rapid medical treatment for psoriasis - PRAC
Time of Update: 2022-04-17
Although, to our knowledge, this is the world's first multidisciplinary early access clinic for the treatment of psoriasis; the benefits of early intervention are recognized for other IMIDs, such as rheumatoid arthritis and Crohn's disease, early Targeted treatment may alter the course of the disease .
-
Front Immunol: a genome-wide association study of ustekinumab response in psoriasis patients
Time of Update: 2022-04-17
Genome-wide association testing was performed on serial outcomes of percent change from baseline in the Psoriasis Area Severity Index (PASI) at 12 weeks of ustekinumab treatment .
-
JEADV: Study on the improvement of hair loss in patients with psoriasis treated with risankizumab
Time of Update: 2022-04-17
Patient-reported alopecia started approximately 12 years ago with a chronic course of remission without any significant and durable improvement with topical/systemic corticosteroids, cyclosporine A, or DPCP .
Reflection confocal microscopy (RCM) examination revealed multiple empty hair follicles as yellow dots with inflammatory cells surrounding the follicles; enlarged dermal papilla with dilated microvessels (Fig.
-
BMJ: Effects of plasma exchange in patients with ANCA-associated vasculitis
Time of Update: 2022-04-17
For the treatment of AAV, plasma exchange had no significant effect on patient mortality, reducing the risk of ESKD at 12 months, but increasing the risk of serious infection .
-
ARD: 2022 American College of Rheumatology/Confederation of European Societies of Rheumatology Microscopic Classification Criteria for Polyangiitis
Time of Update: 2022-04-17
Objectives: The main distinguishing feature between MPA ( microscopic polyangiitis ) and PAN (polyarteritis nodosa ) is the presence of oligoimmune vasculitis in arterioles, venules, or capillaries i
-
Why is the prevalence of pulmonary hypertension higher in patients with mixed connective tissue disease?
Time of Update: 2022-04-16
Mixed connective tissue disease (MCTD) is an autoimmune disease characterized by high serum anti-U1 ribonucleoprotein (U1 RNP) antibody titers, and with systemic lupus erythematosus (SLE), systemic sclerosis (SSc) ) and idiopathic inflammatory myopathy (IIM) with overlapping clinical features) .
-
ARD: Management of Rheumatoid Arthritis in China: A Study on the Implementation of the 2019 EULAR Recommendations
Time of Update: 2022-04-16
Patients from CREDIT were eligible for inclusion in this study if they met the following criteria: newly diagnosed RA according to the 2010 American College of Rheumatology (ACR)/EULAR RA classification criteria , moderate to high disease activity at baseline (Clinical Disease Activity Index (CDAI ) ) >10 ) without severe extra-articular involvement that might affect treatment strategy .
-
ARD: Aging and interferon gamma responses drive a neutrophilic phenotype in inflamed joints
Time of Update: 2022-04-16
Conclusions: Circulating neutrophils in patients with arthritis were similar to healthy controls, but synovial fluid cells exhibited a range of changes that were conserved across species (similar in humans and mice), suggesting that IFN -γ responses and aging are sliding Complementary drivers of fluid neutrophil phenotype .
-
ARD: A phase II randomized trial of the type I interferon inhibitor anivolumab in patients with active lupus nephritis
Time of Update: 2022-04-16
Conclusions: Although the primary endpoint was not met, in patients with active lupus nephritis, anifrugumab IR improved endpoint values including complete renal response at 52 weeks compared with placebo .
-
JEADV: Stress response to 4 inflammatory skin diseases: data analysis of 7273 adult patients with acne, atopic dermatitis, psoriasis, or hidradenitis suppurativa
Time of Update: 2022-04-16
This observational, cross-sectional, non-comparative study by five French patient associations between October 2020 and February 2021 assessed perceptions of adults with AA, AD, P or HS using a digital questionnaire stress, and self-perceived disease severity and quality of life (QoL) in large populations .
-
ARD: A key interaction in a trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide, and the T-cell receptor
Time of Update: 2022-04-16
Purpose: Rheumatoid arthritis (RA) is an autoimmune disease closely related to the major histocompatibility complex (MHC) class II allele DRB1*04:01 , which encodes a combination of Self-peptide as a protein presented to T cells .
-
Front Immunol: A single-cell resolution study of chromatin accessibility in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
Time of Update: 2022-04-16
PBMC, peripheral blood mononuclear cells; scATAC-seq, single-cell sequencing analysis of transposase-accessible chromatin; SLE_PBMC, systemic lupus erythematosus (SLE) patient PBMC; NC_PBMC, normal human PBMC; NK cells, natural killer cells; DC , dendritic cell; TF, transcription factor; TSS, transcription start site .
-
Methotrexate is not effective for 1/3 of rheumatoid patients?
Time of Update: 2022-04-16
In addition, an open-label prospective study of 469 patients with rheumatoid arthritis, grouped according to the age of patients at the start of MTX (10 mg/week) treatment, divided into two groups <65 years old and ≥65 years old, at 8 The two groups were observed in a similar frequency and type of adverse reactions .
-
NEJM: Promising results for iberdomide in stage II systemic lupus erythematosus
Time of Update: 2022-04-16
45mg is superior to placebo in improving the SRI-4 response rate in patients with systemic lupus erythematosus, and subsequent large-scale studies are needed to further confirm the efficacy of iberdomide in the treatment of SLE .
-
J Invest Dermatol: Oral administration of dimethyl fumarate to target HCA2 expression in an imiquimod mouse model
Time of Update: 2022-04-16
e. , keratinocytes, Langerhans cells (LCS), and neutrophils) are involved in the pathogenesis of psoriasis, the aim of this study was to investigate the role of psoriasis-like dermatitis in small The cellular target of DMF treatment of HCA2 was investigated in the murine Imiquimod (Imq) model .
-
ARD: 2022 American College of Rheumatology/European Association of Rheumatology Association classification criteria for eosinophilic granulomatosis with polyangiitis
Time of Update: 2022-04-16
Score-based risk scores for disease classifications were derived in the development set using least absolute shrinkage and selection operator logistic regression, followed by validation of performance feature cases and comparisons in an independent set .
-
JEADV: Clinical Comparison of Suckinumab and Ixekizumab in Pustular and Erythrodermic Psoriasis
Time of Update: 2022-04-16
As for the EP group, it was not possible to demonstrate the efficacy of ixekizumab as previously reported; on the other hand, Suckinumab showed comparable efficacy, with 82% and 54% of patients achieving PASI 90 and PASI 100, respectively, at 48 weeks (Figure 1b) .
